NASA technology utilization program: The small business market

Technology transfer programs were studied to determine how they might be more useful to the small business community. The status, needs, and technology use patterns of small firms are reported. Small business problems and failures are considered. Innovation, capitalization, R and D, and market share problems are discussed. Pocket, captive, and new markets are summarized. Small manufacturers and technology acquisition are discussed, covering external and internal sources, and NASA technology. Small business and the technology utilization program are discussed, covering publications and industrial applications centers. Observations and recommendations include small business market development and contracting, and NASA management technology

Project for the analysis of technology transfer Quarterly report, 1 Jul. - 30 Sep. 1969

Research activities in technology transfer progra

Applications of aerospace technology in industry, a technology transfer profile: Fire safety

The fire safety field is considered as being composed of three parts: an industry, a technology base, and a user base. An overview of the field is presented, including a perspective on the magnitude of the national fire safety problem. Selected NASA contributions to the technology of fire safety are considered. Communication mechanisms, particularly conferences and publications, used by NASA to alert the community to new developments in the fire safety field, are reviewed. Several examples of nonaerospace applications of NASA-generated fire safety technology are also presented. Issues associated with attempts to transfer this technology from the space program to other sectors of the American economy are outlined

Project for the analysis of technology transfer Quarterly report, 1 Oct. - 31 Dec. 1969

Analysis of Tech Brief-Technical Support Package progra

Applications of aerospace technology in industry, a technology transfer profile: Lubrication

Technology transfer in the lubrication field is discussed in terms of the movement of NASA-generated lubrication technology into the private sector as affected by evolving industrial requirements. An overview of the field is presented, and NASA technical contributions to lubrication technology are described. Specific examples in which these technologies have been used in the private sector are summarized

Urinary ATP as an indicator of infection and inflammation of the urinary tract in patients with lower urinary tract symptoms

BACKGROUND: Adenosine-5'-triphosphate (ATP) is a neurotransmitter and inflammatory cytokine implicated in the pathophysiology of lower urinary tract disease. ATP additionally reflects microbial biomass thus has potential as a surrogate marker of urinary tract infection (UTI). The optimum clinical sampling method for ATP urinalysis has not been established. We tested the potential of urinary ATP in the assessment of lower urinary tract symptoms, infection and inflammation, and validated sampling methods for clinical practice. METHODS: A prospective, blinded, cross-sectional observational study of adult patients presenting with lower urinary tract symptoms (LUTS) and asymptomatic controls, was conducted between October 2009 and October 2012. Urinary ATP was assayed by a luciferin-luciferase method, pyuria counted by microscopy of fresh unspun urine and symptoms assessed using validated questionnaires. The sample collection, storage and processing methods were also validated. RESULTS: 75 controls and 340 patients with LUTS were grouped as without pyuria (n = 100), pyuria 1-9 wbc ?l(-1) (n = 120) and pyuria ?10 wbc ?l(-1) (n = 120). Urinary ATP was higher in association with female gender, voiding symptoms, pyuria greater than 10 wbc ?l(-1) and negative MSU culture. ROC curve analysis showed no evidence of diagnostic test potential. The urinary ATP signal decayed with storage at 23°C but was prevented by immediate freezing at ??-20°C, without boric acid preservative and without the need to centrifuge urine prior to freezing. CONCLUSIONS: Urinary ATP may have a role as a research tool but is unconvincing as a surrogate, clinical diagnostic marker

A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/75555/1/j.1742-1241.2007.01491.x.pd

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes

Introduction Overactive bladder (OAB) is a prevalent and potentially debilitating syndrome that significantly impairs quality of life. Mirabegron and vibegron are β3-adrenoceptor (β3AR) agonists that provide a different mechanism of action to antimuscarinic medications. Vibegron has high β3AR selectivity and enhances detrusor relaxation without compromising voiding function. This review summarises the clinical and real-world evidence supporting the efficacy, safety and patient-reported benefits of vibegron in OAB. Methods A comprehensive search of the PubMed database was conducted in December 2024 using the keyword "vibegron". This search yielded 123 entries, which were subsequently screened by title for relevance to the objectives of this narrative review. All relevant articles identified through this process were included. Results Pivotal phase III trials have demonstrated significant reductions in urgency, urinary frequency and urgency urinary incontinence with vibegron, with rapid onset of action and a more favourable tolerability profile than antimuscarinics. The benefits of vibegron were consistent across diverse patient populations, including older adults and those with concomitant benign prostatic hyperplasia. Real-world data further suggest that vibegron is associated with improved adherence and persistence compared with other OAB therapies. Additionally, cardiovascular safety studies confirm that vibegron has no clinically significant effects on blood pressure or heart rate. While comparative trials with mirabegron indicate similar efficacy, vibegron’s higher β3AR selectivity and lack of cytochrome P450 interactions offer advantages in specific patient groups. Ongoing research, including real-world phase IV studies, aims to further define the long-term effectiveness and safety of vibegron in clinical practice. Conclusion Vibegron represents an important advance in the pharmacologic management of OAB, providing a well-tolerated and effective alternative to existing therapies